List of Excipients in Branded Drug LEQEMBI

« Back to Dashboard

Leqembi Excipient Strategy and Commercial Opportunities

Last updated: October 30, 2026

Leqembi, the brand name for lecanemab-irmb, uses a relatively simple intravenous monoclonal-antibody formulation built around histidine buffering, arginine hydrochloride for protein stability, polysorbate 80 for interfacial protection, and water for injection. The commercial opportunity is concentrated in high-quality excipients, sterile fill-finish, container-closure systems, infusion supplies, cold-chain logistics, and future subcutaneous or extended-interval formulations.

The current U.S. product is a 100 mg/mL sterile concentrate supplied in single-dose vials. The approved regimen is 10 mg/kg by intravenous infusion every two weeks. The U.S. Food and Drug Administration granted traditional approval on July 6, 2023, after accelerated approval in January 2023.[1]

What excipients are used in Leqembi?

Leqembi contains four named excipients in the drug product:

Component	Amount per mL of Leqembi concentrate	Primary formulation function
Arginine hydrochloride	3.7 mg	Protein stabilization and aggregation control
Histidine	1.5 mg	Buffering
Histidine hydrochloride monohydrate	0.7 mg	Histidine buffer system and pH control
Polysorbate 80	0.5 mg	Surfactant and protection against agitation-induced aggregation
Water for injection	q.s.	Injectable vehicle

The product has a target pH near 5.0 and is supplied as a preservative-free solution. The formulation is diluted before administration in 0.9% sodium chloride injection.[1]

The excipient profile is commercially attractive because it relies on established materials rather than a novel delivery excipient. That reduces regulatory complexity but shifts competitive differentiation toward pharmaceutical grade, low-bioburden manufacturing, lot consistency, impurity control, and supply reliability.

How much excipient does a typical Leqembi patient use?

At the labeled dose of 10 mg/kg every two weeks, a 70 kg patient receives 700 mg of lecanemab per infusion. At a concentration of 100 mg/mL, this requires approximately 7 mL of Leqembi concentrate per dose.

A 70 kg patient receiving 26 annual infusions would use approximately:

Material	Approximate annual use per patient
Leqembi concentrate	182 mL
Lecanemab	18.2 g
Arginine hydrochloride	0.67 g
Histidine	0.27 g
Histidine hydrochloride monohydrate	0.13 g
Polysorbate 80	0.09 g

The excipient mass per patient is small relative to the active ingredient. The commercial value is therefore driven by patient volume, manufacturing scale, quality specifications, and the need for redundant supply rather than by the quantity of excipient in each vial.

The larger recurring opportunity is the complete administration chain: drug substance, sterile drug product, dilution bags, infusion tubing, filters, compounding services, refrigerated distribution, and monitoring infrastructure.

What is the formulation strategy behind Leqembi?

Leqembi uses a conventional liquid biologic formulation strategy with four technical objectives.

Protein stability

Arginine hydrochloride is commonly used in biologic formulations to reduce protein-protein interactions and limit aggregation. For an anti-amyloid antibody administered repeatedly over a long treatment period, control of soluble aggregates and subvisible particles is important for product quality and infusion tolerability.

pH control

The histidine and histidine hydrochloride pair provides buffering near the product's acidic pH. Histidine systems are widely used for monoclonal antibodies because they can provide suitable buffering capacity while maintaining acceptable compatibility with proteins and injectable administration.

Interfacial protection

Polysorbate 80 reduces adsorption and aggregation at air-liquid and liquid-surface interfaces. This is relevant during vial filling, shipping, dilution, and infusion. Polysorbate degradation can generate subvisible particles and reactive species, so supplier controls for peroxides, hydroperoxides, aldehydes, and fatty-acid composition are commercially important.

Administration compatibility

The product is diluted into normal saline before infusion. A formulation that does not require a proprietary delivery device or specialized reconstitution step lowers the barrier to adoption in hospitals and infusion centers.

What commercial opportunities exist for Leqembi excipient suppliers?

The strongest opportunities are in high-specification versions of conventional excipients and in services surrounding the finished drug.

Pharmaceutical-grade arginine hydrochloride

Arginine hydrochloride is a relatively low-cost material, but biologic manufacturers require tight control of identity, purity, endotoxins, bioburden, elemental impurities, and batch-to-batch variability. Suppliers able to provide validated pharmaceutical-grade material with dual-region manufacturing capacity can compete for strategic supply agreements.

The opportunity is more likely to be based on quality and continuity than on premium pricing per kilogram.

Histidine and histidine hydrochloride

Leqembi uses both histidine and histidine hydrochloride monohydrate. Suppliers can compete on:

• Low endotoxin and bioburden profiles
• Consistent water content
• Low trace-metal content
• Global regulatory documentation
• Reliable supply of both components from coordinated manufacturing networks
• Change-control support for biologics manufacturers

A supplier that can provide the complete histidine buffer system can reduce qualification and procurement complexity for Eisai and its manufacturing partners.

Polysorbate 80

Polysorbate 80 is the highest-value excipient opportunity in the formulation because it has a direct relationship with biologic stability and product quality. Not all polysorbate 80 is interchangeable for a monoclonal antibody.

Commercial differentiation can include:

• Controlled peroxide and hydroperoxide levels
• Defined fatty-acid distribution
• Low aldehyde formation
• Low particulate burden
• Traceability of raw materials
• Improved stability under refrigerated storage
• Analytical methods for degradation monitoring

Polysorbate 80 suppliers with strong biologics experience may have greater leverage than commodity suppliers of arginine or histidine.

Excipient testing and analytical services

Leqembi creates demand for analytical testing of both incoming excipients and finished product. Relevant services include:

• Polysorbate degradation testing
• Subvisible and visible particle testing
• Protein aggregation analysis
• Extractables and leachables testing
• Container-closure integrity testing
• Forced-degradation studies
• Stability-indicating assay development
• Comparability testing following excipient or supplier changes

These services can remain commercially relevant even if the excipient composition does not change.

What manufacturing and packaging opportunities are linked to Leqembi?

The product is supplied in single-dose vials and requires refrigerated handling. The commercial opportunity extends beyond excipients into sterile biologics manufacturing.

Sterile fill-finish

Leqembi requires aseptic filling of a protein solution into sterile single-dose vials. Contract manufacturers can compete on:

• Low-shear processing
• Controlled hold times
• Low-particle filling
• High-speed vial filling
• Automated visual inspection
• Lyophilization capacity if future formulations require it
• Regulatory experience with monoclonal antibodies

Because the current product is a liquid, companies with liquid biologic fill-finish capacity have a more direct opportunity than facilities designed only for lyophilized products.

Vials and elastomeric closures

Container-closure suppliers can target:

• Low-extractable glass vials
• Low-particulate stoppers
• Coated elastomers
• Improved seal integrity
• Reduced adsorption of antibody to contact surfaces
• Compatible crimp seals and vial finishes

Polysorbate-containing biologics can be sensitive to contact materials and trace contaminants. Container-closure changes may require extensive comparability work, which can create switching barriers for incumbent suppliers.

Infusion materials

The labeled product is diluted in 0.9% sodium chloride and administered intravenously. Opportunities include:

• Premixed saline bags
• Low-sorption infusion bags
• Tubing sets
• In-line filters
• Closed-system transfer devices
• Pharmacy compounding services
• Infusion-center inventory management

An average 70 kg patient receives 26 infusions each year. That creates recurring demand for administration supplies even when the volume of excipient used per dose is modest.

How strong is the formulation patent estate for Leqembi?

Leqembi is a biologic, so its competitive protection is divided among regulatory exclusivity, antibody patents, formulation patents, manufacturing patents, and method-of-use patents.

The exact commercial strength of the estate cannot be inferred from the excipient list alone. Arginine hydrochloride, histidine, histidine hydrochloride, polysorbate 80, and water for injection are established excipients. A patent claim limited to those ingredients would face potential validity and obviousness challenges unless it captured a specific concentration range, stability result, aggregation profile, impurity limit, or manufacturing process.

The stronger protection areas are likely to include:

• The anti-amyloid antibody sequence
• Binding characteristics and epitopes
• Use in Alzheimer’s disease
• Dosing schedules
• Patient-selection criteria
• MRI-monitoring or treatment-management protocols
• Liquid formulation ranges
• Aggregation control
• Manufacturing and purification methods
• Subcutaneous or alternative delivery systems

A formulation patent becomes more defensible when it links a defined excipient range to an unexpected technical result, such as improved stability, lower particle generation, reduced viscosity, or improved shelf life.

What is the FDA regulatory status of Leqembi?

Regulatory event	Date
Accelerated approval	January 6, 2023
Traditional approval	July 6, 2023
Dosage form	Intravenous infusion concentrate
Strength	100 mg/mL
Labeled dose	10 mg/kg every two weeks
Reference-product category	Biologic
Relevant FDA pathway for follow-on products	Biosimilar or interchangeable biosimilar pathway

Traditional approval followed the confirmatory Clarity AD trial. The FDA labeling identifies the risk of amyloid-related imaging abnormalities, including edema and hemorrhage, which affects patient selection, MRI monitoring, and treatment management.[1,2]

Does Leqembi have Orange Book listings or Paragraph IV challenges?

Leqembi is a biologic, not a conventional small-molecule drug. Its core regulatory protection is therefore not managed through the standard Orange Book and abbreviated new drug application pathway.

Paragraph IV challenges are designed for small-molecule products submitted under section 505(j) of the Federal Food, Drug, and Cosmetic Act. A competing lecanemab product would generally need to use the Public Health Service Act biosimilar pathway rather than file an ANDA with Paragraph IV certification.

The relevant questions are:

• Whether the competitor can demonstrate biosimilarity
• Whether it seeks an interchangeable designation
• Which patents are identified in the biologics patent-exchange process
• Whether the reference-product exclusivity period has expired
• Whether antibody, method-of-use, formulation, or manufacturing patents remain enforceable

The reference product received U.S. licensure in July 2023. Under the Biologics Price Competition and Innovation Act, a biosimilar application generally cannot be submitted until four years after first licensure, and approval generally cannot occur until 12 years after first licensure, subject to statutory exceptions and patent litigation.[3]

When could biosimilar competition affect Leqembi?

The statutory reference-product exclusivity framework points to July 2035 as the earliest general approval milestone based solely on the 12-year period from traditional licensure. The four-year application-submission milestone falls in July 2027.

These dates do not determine actual market entry. Patent litigation, settlement agreements, manufacturing readiness, FDA review, and the scope of any biosimilar or interchangeable designation can change the commercial timeline.

Potential biosimilar development barriers include:

• Access to sufficient reference product for analytical and clinical work
• Demonstration of high similarity across critical quality attributes
• Control of aggregates and subvisible particles
• Matching glycosylation and charge variants
• Reproducing stability in the presence of polysorbate 80
• Establishing comparable immunogenicity
• Conducting large-scale sterile manufacturing
• Supporting administration and MRI-monitoring requirements

The need for repeated dosing increases the value of a lower-cost biosimilar, but it also increases the consequences of small differences in immunogenicity, stability, or administration performance.

How does Leqembi compare with competing Alzheimer’s biologics?

Product	Active ingredient	Manufacturer	Administration	Excipient opportunity
Leqembi	Lecanemab-irmb	Eisai/Biogen	IV every two weeks	High-volume recurring infusion and biologics supply chain
Aduhelm	Aducanumab-avwa	Biogen	IV monthly	Similar antibody excipient and infusion requirements
Kisunla	Donanemab-azbt	Eli Lilly	IV at defined intervals	Competing anti-amyloid formulation and infusion demand

Leqembi has an important commercial distinction: treatment is administered every two weeks under the original U.S. regimen. That increases annual demand for vials, saline, infusion sets, pharmacy labor, and monitoring compared with less frequent products.

The commercial advantage for excipient suppliers is recurring volume. The disadvantage is that hospitals and manufacturers may seek procurement consolidation across multiple antibody products using similar excipient systems.

What generic launch risks exist for Leqembi?

A conventional generic launch is not the principal risk. The more relevant risk is biosimilar entry combined with lifecycle management.

Potential entry scenarios include:

1. A biosimilar antibody using a comparable liquid formulation and the same broad excipient classes.
2. A product with an alternative buffer or surfactant system supported by comparability data.
3. A subcutaneous formulation that reduces infusion-center use.
4. An extended-interval product that reduces annual administration frequency.
5. A follow-on antibody with a different dosing or monitoring profile.

For excipient suppliers, the main risk is that a future formulation eliminates or changes polysorbate 80, reduces concentration, moves to a solid-state product, or uses a device-compatible subcutaneous formulation.

What licensing and partnership opportunities exist?

Commercial opportunities are most likely to arise through supply and development agreements rather than a public license to the Leqembi excipient formula.

Relevant partnership structures include:

• Long-term supply contracts for pharmaceutical-grade polysorbate 80
• Dual-source agreements for histidine and arginine hydrochloride
• Co-development of low-peroxide surfactants
• Contract analytical testing for biologic stability
• Fill-finish and packaging agreements
• Regional distribution and cold-chain partnerships
• Device partnerships for subcutaneous delivery
• Biosimilar formulation and process-development collaborations

No public licensing agreement should be assumed solely from the approved excipient composition. The product label identifies formulation components but does not establish supplier identity, exclusivity, pricing, or purchasing commitments.

What is the commercial outlook for Leqembi excipients?

The near-term opportunity is strongest for:

• Polysorbate 80 with tight oxidative impurity controls
• Sterile liquid biologic fill-finish
• Low-extractable vial and stopper systems
• Analytical services for particles and surfactant degradation
• Infusion consumables
• Cold-chain and hospital pharmacy services

The long-term opportunity depends on lifecycle expansion. A move to subcutaneous dosing could increase demand for high-concentration formulations, prefilled systems, autoinjectors, and device-compatible excipients while reducing infusion-related demand.

The most defensible commercial position is therefore not ownership of a conventional excipient molecule. It is validated performance in a sensitive monoclonal-antibody formulation, supported by regulatory history, supply continuity, and demonstrated control of degradation products.

Key Takeaways

• Leqembi uses arginine hydrochloride, histidine, histidine hydrochloride monohydrate, polysorbate 80, and water for injection.
• Polysorbate 80 is the most technically differentiated excipient in the formulation because oxidation and degradation can affect antibody quality.
• The current product is a 100 mg/mL IV concentrate diluted in normal saline and administered every two weeks.
• A 70 kg patient uses approximately 182 mL of concentrate and 26 infusion administrations per year.
• The major commercial opportunities are high-quality excipient supply, sterile fill-finish, packaging, analytical testing, infusion materials, and cold-chain services.
• Leqembi is regulated as a biologic. Orange Book and Paragraph IV strategies are generally not the primary competitive pathways.
• The reference product received traditional FDA approval on July 6, 2023. The general 12-year biologic exclusivity framework points to July 2035 for the earliest approval milestone absent other legal constraints.
• Future subcutaneous or extended-interval formulations could materially change excipient demand and reduce reliance on infusion-center infrastructure.

FAQs

Is polysorbate 80 the main excipient opportunity for Leqembi?

Yes. Its concentration is low, but its impact on aggregation, particles, oxidation, and stability makes it more technically important than the buffer components.

Can a biosimilar use the same Leqembi excipients?

Yes. A biosimilar may use the same excipient classes if its formulation and manufacturing process support the required comparability, quality, safety, and stability data.

Does Leqembi require a preservative?

No. The approved product is a preservative-free, single-dose injectable biologic.

Could a future Leqembi formulation eliminate intravenous infusion?

A subcutaneous or other alternative delivery system could reduce infusion requirements, but it would require new formulation, device, stability, pharmacokinetic, and regulatory development.

Are Leqembi excipients protected by a standalone patent?

The named excipients are established pharmaceutical materials. Commercial protection is more likely to depend on specific concentration ranges, stability results, manufacturing controls, antibody claims, and regulatory exclusivity than on ownership of the excipient molecules themselves.

References

1. U.S. Food and Drug Administration. (2023). Leqembi (lecanemab-irmb) injection: Prescribing information.
2. van Dyck, C. H., Swanson, C. J., Aisen, P., et al. (2023). Lecanemab in early Alzheimer’s disease. New England Journal of Medicine, 388(1), 9-21.
3. U.S. Food and Drug Administration. (2020). Questions and answers on biosimilar development and the BPCI Act.